Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive TCR Raises $5.8M to Invest in Clinical Applications


This story was originally published June 9.

Seattle-based Adaptive TCR, which provides immune repertoire sequencing services, has raised $5.8 million from private investors in a Series B investment round, the company reported last week.

The new financing adds to $4.5 million that the company secured last year, when it first launched its service (IS 7/20/2010).

This latest investment will be used to grow the company's immune system sequencing service, immunoSeq, and "invest in clinical applications in the oncology, autoimmune, and vaccine fields," CEO Chad Robins said in a statement.

According to Adaptive TCR, its platform can be used by biotech and pharmaceutical companies to predict whether patients will respond to certain therapeutics or vaccines. The company is currently testing its technology in a pilot program to sequence the T-cells and B-cells of volunteers, searching for marks of exposure to 17 different pathogens (CSN 4/12/2011).

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.